整合酶链转移抑制剂（INSTIs）与孕期体重增加 - Suppr | 超能文献

相似文献

1

INSTIs and weight gain in pregnancy.整合酶链转移抑制剂（INSTIs）与孕期体重增加

Lancet HIV. 2020 Oct;7(10):e663-e665. doi: 10.1016/S2352-3018(20)30251-4.

2

Switch to INSTIs, but Not Long-Term Stable INSTIs, Is Associated With Excess Weight Gain in People Living With HIV.改用整合酶链转移抑制剂（INSTIs），但非长期稳定使用INSTIs，与HIV感染者体重过度增加有关。

J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):e36-e38. doi: 10.1097/QAI.0000000000002802.

3

HIV Drug May Increase Risk of Neural Tube Birth Defects.抗艾滋病病毒药物可能会增加神经管出生缺陷的风险。

Am J Nurs. 2019 Jan;119(1):27. doi: 10.1097/01.NAJ.0000552605.35664.bc.

4

Dolutegravir becomes first choice for HIV.多替拉韦成为治疗艾滋病病毒的首选药物。

Lancet Infect Dis. 2019 Sep;19(9):937-938. doi: 10.1016/S1473-3099(19)30438-4.

5

Dolutegravir Use at Conception - Additional Surveillance Data from Botswana.多替拉韦在受孕时的使用——来自博茨瓦纳的更多监测数据。

N Engl J Med. 2019 Aug 29;381(9):885-887. doi: 10.1056/NEJMc1908155. Epub 2019 Jul 22.

6

Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy.整合酶抑制剂治疗与代谢综合征和糖尿病风险。

Curr Opin Infect Dis. 2021 Feb 1;34(1):16-24. doi: 10.1097/QCO.0000000000000695.

7

[Use of raltegravir in pregnant HIV-1 infected women: experience in different clinical scenarios].[拉替拉韦在感染HIV-1的孕妇中的应用：不同临床场景下的经验]

Enferm Infecc Microbiol Clin. 2014 Nov;32(9):616-8. doi: 10.1016/j.eimc.2014.01.006. Epub 2014 Feb 17.

8

[Dolutegravir in acute HIV-1 infection: first reported case].[多替拉韦用于急性HIV-1感染：首例报告病例]

Rev Esp Quimioter. 2019 Aug;32(4):387-389. Epub 2019 Jul 11.

9

Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?整合酶抑制剂：10 年经验之后，最好的时代是否即将到来？

Pharmacotherapy. 2019 May;39(5):576-598. doi: 10.1002/phar.2246. Epub 2019 Apr 1.

10

Dolutegravir for pregnant women living with HIV.多替拉韦用于感染艾滋病毒的孕妇。

CMAJ. 2020 Mar 2;192(9):E217-E218. doi: 10.1503/cmaj.191227.

引用本文的文献

1

Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084.评估长效卡博特韦在非洲东部和南部孕妇中的安全性和药代动力学：HPTN 084的二次分析

J Int AIDS Soc. 2025 Jan;28(1):e26401. doi: 10.1002/jia2.26401.

2

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.孕期及产后使用含多替拉韦和替诺福韦艾拉酚胺富马酸盐的抗逆转录病毒治疗方案与体重变化及不良妊娠结局的关系。

Clin Infect Dis. 2024 Jun 14;78(6):1617-1628. doi: 10.1093/cid/ciae001.

3